LB Pharmaceuticals Inc (LBRX) Reiterated at Buy by Stifel Post CEO, CFO Chat

Stifel analyst Paul Matteis reiterated a Buy rating and $53.00 price target on LB Pharmaceuticals Inc (NASDAQ: LBRX).

The analyst commented, "We're reiterating our Buy rating on LBRX, after spending time with CEO Heather Turner, COO/CBO Gad Soffer, and CFO Joseph Miller at an investor lunch/NDR. For the upcoming ph3 schizophrenia readout in 1H27, our optimism on LB-102 is anchored around (1) its shared mechanism with amisulpride, which is approved ex-US for schizophrenia on the basis of multiple successful RCTs, (2) positive ph2 schizophrenia study for LB-102 which supports a better safety profile vs the approved atypicals, and (3) management commentary around study execution including measures to mitigate placebo, along with a larger N and longer duration to improve power. Overall, we think LBRX offers an attractive catalyst path ahead with the more de-risked schizophrenia readout, plus shots-ongoal in mood disorders including ph2 BPD (1Q28) and adjunctive MDD (1H29) studies--we also discussed LB's plans to study '102 in schizophrenia negative symptoms and AD agitation/psychosis which are very large market opportunities."

For an analyst ratings summary and ratings history on LB Pharmaceuticals Inc click here. For more ratings news on LB Pharmaceuticals Inc click here.

Shares of LB Pharmaceuticals Inc closed at $41.00 yesterday.

You May Also Be Interested In

• Inter Parfums (IPAR) Tops Q3 EPS by 33c ; Offers Guidance
• Tutor Perini (TPC) Tops Q3 EPS by 92c; Offers Guidance
• TrueBlue (TBI) Tops Q3 EPS by 16c, Beats on Revenue